Role of high mobility group box protein 1 in depression: A mechanistic and therapeutic perspective
- PMID: 35978968
- PMCID: PMC9258272
- DOI: 10.5498/wjp.v12.i6.779
Role of high mobility group box protein 1 in depression: A mechanistic and therapeutic perspective
Abstract
As a common and serious psychiatric disorder, depression significantly affects psychosocial functioning and quality of life. However, the mechanism of depression is still enigmatic and perplexing, which limits its precise and effective therapeutic methods. Recent studies demonstrated that neuroinflammation activation plays an important role in the pathophysiology of depression. In this respect, high mobility group box 1 (HMGB1) may be a possible signaling inducer of neuroinflammation and can be a potential mechanistic and therapeutic target for depression. Herein, we review recent studies on the mechanistic and therapeutic targets of HMGB1 in depression and propose potential perspectives on this topic.
Keywords: Depression; High mobility group box 1; Mechanism; Neuroinflammation; Perspective; Review.
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Figures
Similar articles
-
Molecular insights into the therapeutic promise of targeting HMGB1 in depression.Pharmacol Rep. 2021 Feb;73(1):31-42. doi: 10.1007/s43440-020-00163-6. Epub 2020 Oct 4. Pharmacol Rep. 2021. PMID: 33015736 Review.
-
The Potential Therapeutic Role of the HMGB1-TLR Pathway in Epilepsy.Curr Drug Targets. 2021;22(2):171-182. doi: 10.2174/1389450121999200729150443. Curr Drug Targets. 2021. PMID: 32729417 Review.
-
Arctigenin protects against depression by inhibiting microglial activation and neuroinflammation via HMGB1/TLR4/NF-κB and TNF-α/TNFR1/NF-κB pathways.Br J Pharmacol. 2020 Nov;177(22):5224-5245. doi: 10.1111/bph.15261. Epub 2020 Oct 19. Br J Pharmacol. 2020. PMID: 32964428 Free PMC article.
-
High mobility group box 1 (HMGB1) protein in Multiple Sclerosis (MS): Mechanisms and therapeutic potential.Life Sci. 2019 Dec 1;238:116924. doi: 10.1016/j.lfs.2019.116924. Epub 2019 Oct 10. Life Sci. 2019. PMID: 31606383 Review.
-
Icariin and icaritin ameliorated hippocampus neuroinflammation via mediating HMGB1 expression in social defeat model in mice.Int Immunopharmacol. 2019 Oct;75:105799. doi: 10.1016/j.intimp.2019.105799. Epub 2019 Aug 8. Int Immunopharmacol. 2019. PMID: 31401387
Cited by
-
Brain but not serum BDNF levels are associated with structural alterations in the hippocampal regions in patients with drug-resistant mesial temporal lobe epilepsy.Front Neurosci. 2023 Jul 19;17:1217702. doi: 10.3389/fnins.2023.1217702. eCollection 2023. Front Neurosci. 2023. PMID: 37539386 Free PMC article.
-
Paeoniflorin and depression: a comprehensive review of underlying molecular mechanisms.Metab Brain Dis. 2025 Jul 19;40(6):241. doi: 10.1007/s11011-025-01671-1. Metab Brain Dis. 2025. PMID: 40682677 Review.
-
Amomum tsao-ko crevost et lemaire ameliorates depression-like behaviors and hippocampal inflammation by inhibiting microglia activation and HMGB1/TLR4/NF-κB pathway in diabetic mice with depression.Metab Brain Dis. 2025 Mar 28;40(4):164. doi: 10.1007/s11011-025-01592-z. Metab Brain Dis. 2025. PMID: 40153044
-
Serum HMGB1 as a diagnostic biomarker and mediator of childhood trauma in adolescent depression.Front Psychiatry. 2025 Jun 10;16:1584320. doi: 10.3389/fpsyt.2025.1584320. eCollection 2025. Front Psychiatry. 2025. PMID: 40557138 Free PMC article.
-
Translocation of High Mobility Group Box 1 From the Nucleus to the Cytoplasm in Depressed Patients With Epilepsy.ASN Neuro. 2022 Jan-Dec;14:17590914221136662. doi: 10.1177/17590914221136662. ASN Neuro. 2022. PMID: 36383501 Free PMC article.
References
-
- Tran BX, Ha GH, Nguyen DN, Nguyen TP, Do HT, Latkin CA, Ho CSH, Ho RCM. Global mapping of interventions to improve quality of life of patients with depression during 1990-2018. Qual Life Res. 2020;29:2333–2343. - PubMed
-
- GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–1858. - PMC - PubMed
-
- Liu Q, He H, Yang J, Feng X, Zhao F, Lyu J. Changes in the global burden of depression from 1990 to 2017: Findings from the Global Burden of Disease study. J Psychiatr Res. 2020;126:134–140. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials